Skip to content

Bausch Health Companies BHC Salix — Additions

Other segment segments

Bausch + Lomb
$0-100%
Diversified
$0
International
$0
Solta Medical
$0-100%

Similar metrics at other companies

Voya Financial logo
VOYAHealth Solutions Segment — Additions from business combinations
$0
Central Garden & Pet Company logo
CENTGarden Products Segment — Additions in fiscal year
$0
CBIZ logo
CBZFinancial Services — Additions
$3.01M+542%
International Business Machines logo
IBMOther — Goodwill Additions
$0
Voya Financial logo
VOYAWealth Solutions Segment — Additions from business combinations
$0-100%
Aveanna Healthcare Holdings Inc. logo
AVAHMedical Solutions — Goodwill Acquired
$0

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$1.86B-15.9%

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's salix — additions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch Health Companies's salix — additions?
Bausch Health Companies (BHC) reported salix — additions of $0 in Q1 2026.
What does salix — additions mean?
Captures the value of new goodwill recognized during the reporting period specifically attributable to the Salix segment, typically resulting from business combinations or acquisitions. This metric indicates the company's inorganic growth activity within its core pharmaceutical segments. It reflects capital deployed to expand the segment's market footprint or product pipeline.